NCT05991336
Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary endpoint(s) modified.
See at-risk trials from Institute of Hematology & Blood Diseases Hospital, China
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion moved earlier from Dec 31, 2028 to Dec 31, 2027
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 20 words
- Study completion moved earlier from Dec 31, 2029 to Dec 31, 2028
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Growth in pediatric subjects will be assessed by height.
Timeframe: Up to 5 years.
Growth in pediatric subjects will be assessed by weight.
Timeframe: Up to 5 years.
Growth in pediatric subjects will be assessed by bone density.
Timeframe: Up to 5 years.
The pubertal status will be measured using by Tanner scale.
Timeframe: Up to 5 years.
Quality of life will be measured using by Pediatric Quality of Life Inventory (PedsQL) at baseline and the end of the study.
Timeframe: Up to 5 years.
Arms and interventions
Gene therapy group
TDT Children who have received gene therapy between 3\~14 years old.
Supportive therapy group
TDT Children who received lifelong treatment with blood transfusions and iron chelation. They were selected based on the age and sex of the gene therapy group.
Healthy children group
Healthy children were selected based on the age and sex of the gene therapy group.
Genetic: Gene therapy
Sites
1 site in 1 country
- Regenerative Medicine CenterTianjin, Tianjin Municipality, China